Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 3/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.47 |
| ▸ | CCR2 | P41597 | 3/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13864851 | 0.83 | CCR2 (0.50) | PLD2PLD1CCR2AVPR1AKMT2A | |
| SCHEMBL5003859 | 0.83 | PLD2 (0.44) | PLD2PLD1CCR2AVPR1AF11 | |
| SCHEMBL2102054 | 0.82 | AVPR1A (0.56) | PLD2PLD1AVPR1AF11RORC | |
| SCHEMBL631308 | 0.79 | KMT2A (0.46) | PLD2PLD1CCR2KMT2APGR | |
| SCHEMBL4999332 | 0.78 | CCR2 (0.49) | PLD2PLD1CCR2TDP1TP53 | |
| SCHEMBL4999331 | 0.78 | CCR2 (0.49) | PLD2PLD1CCR2TDP1TP53 | |
| SCHEMBL1949004 | 0.78 | IP6K1 (0.54) | KMT2APGRCYP3A4MAPT | |
| SCHEMBL4982133 | 0.78 | IP6K1 (0.54) | KMT2APGRCYP3A4MAPT | |
| SCHEMBL4999323 | 0.77 | PLD2 (0.47) | PLD2PLD1CCR2AVPR1AF11 | |
| SCHEMBL631301 | 0.77 | PLD2 (0.49) | PLD2PLD1CCR2TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | PLD2 3476/4885PLD1 2942/4885CCR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.